{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T07:19:57Z","timestamp":1785223197454,"version":"3.55.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T00:00:00Z","timestamp":1668556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T00:00:00Z","timestamp":1668556800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"crossref","award":["2018YFC0116800"],"award-info":[{"award-number":["2018YFC0116800"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Suzhou Municipal Science and Technology Program","award":["SYS2018009"],"award-info":[{"award-number":["SYS2018009"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82073328"],"award-info":[{"award-number":["82073328"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Definitive concurrent chemoradiotherapy (CCRT) is the standard treatment for locally advanced non-small cell lung cancer (LANSCLC) patients, but the treatment response and survival outcomes varied among these patients. We aimed to identify pretreatment computed tomography-based radiomics features extracted from tumor and tumor organismal environment (TOE) for long-term survival prediction in these patients treated with CCRT.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A total of 298 eligible patients were randomly assigned into the training cohort and validation cohort with a ratio 2:1. An integrated feature selection and model training approach using support vector machine combined with genetic algorithm was performed to predict 3-year overall survival (OS). Patients were stratified into the high-risk and low-risk group based on the predicted survival status. Pulmonary function test and blood gas analysis indicators were associated with radiomic features. Dynamic changes of peripheral blood lymphocytes counts before and after CCRT had been documented.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Nine features including 5 tumor-related features and 4 pulmonary features were selected in the predictive model. The areas under the receiver operating characteristic curve for the training and validation cohort were 0.965 and 0.869, and were reduced by 0.179 and 0.223 when all pulmonary features were excluded. Based on radiomics-derived stratification, the low-risk group yielded better 3-year OS (68.4% vs. 3.3%, p\u2009&lt;\u20090.001) than the high-risk group. Patients in the low-risk group had better baseline FEV1\/FVC% (96.3% vs. 85.9%, p\u2009=\u20090.046), less Grade\u2009\u2265\u20093 lymphopenia during CCRT (63.2% vs. 83.3%, p\u2009=\u20090.031), better recovery of lymphopenia from CCRT (71.4% vs. 27.8%, p\u2009&lt;\u20090.001), lower incidence of Grade\u2009\u2265\u20092 radiation-induced pneumonitis (31.6% vs. 53.3%, p\u2009=\u20090.040), superior tumor remission (84.2% vs. 66.7%, p\u2009=\u20090.003).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Pretreatment radiomics features from tumor and TOE could boost the long-term survival forecast accuracy in LANSCLC patients, and the predictive results could be utilized as an effective indicator for survival risk stratification. Low-risk patients might benefit more from radical CCRT and further adjuvant immunotherapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration:<\/jats:title>\n                <jats:p>retrospectively registered.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13014-022-02136-w","type":"journal-article","created":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T12:04:07Z","timestamp":1668600247000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["CT radiomics-based long-term survival prediction for locally advanced non-small cell lung cancer patients treated with concurrent chemoradiotherapy using features from tumor and tumor organismal environment"],"prefix":"10.1186","volume":"17","author":[{"given":"Nai-Bin","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Feng","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chu","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi-Wen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Hang","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Yu","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang-Qiang","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan-Miao","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,16]]},"reference":[{"issue":"1","key":"2136_CR1","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1038\/s41598-017-02739-4","volume":"7","author":"Z Zhou","year":"2017","unstructured":"Zhou Z, Song X, Wu A, Liu H, Wu H, Wu Q, et al. Pulmonary emphysema is a risk factor for radiation pneumonitis in NSCLC patients with squamous cell carcinoma after thoracic radiation therapy. Sci Rep. 2017;7(1):2748.","journal-title":"Sci Rep"},{"issue":"1","key":"2136_CR2","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13014-018-1030-1","volume":"13","author":"F Li","year":"2018","unstructured":"Li F, Zhou Z, Wu A, Cai Y, Wu H, Chen M, et al. Preexisting radiological interstitial lung abnormalities are a risk factor for severe radiation pneumonitis in patients with small-cell lung cancer after thoracic radiation therapy. Radiat Oncol. 2018;13(1):82.","journal-title":"Radiat Oncol"},{"issue":"10","key":"2136_CR3","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1200\/JCO.1995.13.10.2606","volume":"13","author":"M Roach III","year":"1995","unstructured":"Roach M 3rd, Gandara DR, Yuo HS, Swift PS, Kroll S, Shrieve DC, et al. Radiation pneumonitis following combined modality therapy for lung cancer: analysis of prognostic factors. J Clin Oncol. 1995;13(10):2606\u201312.","journal-title":"J Clin Oncol"},{"issue":"4","key":"2136_CR4","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.ijrobp.2007.04.077","volume":"69","author":"JD Bradley","year":"2007","unstructured":"Bradley JD, Hope A, El Naqa I, Apte A, Lindsay PE, Bosch W, et al. A nomogram to predict radiation pneumonitis, derived from a combined analysis of RTOG 9311 and institutional data. Int J Radiat Oncol Biol Phys. 2007;69(4):985\u201392.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"2136_CR5","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.ijrobp.2005.11.046","volume":"65","author":"AJ Hope","year":"2006","unstructured":"Hope AJ, Lindsay PE, El Naqa I, Alaly JR, Vicic M, Bradley JD, et al. Modeling radiation pneumonitis risk with clinical, dosimetric, and spatial parameters. Int J Radiat Oncol Biol Phys. 2006;65(1):112\u201324.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"16","key":"2136_CR6","doi-asserted-by":"publisher","first-page":"6105","DOI":"10.1088\/0031-9155\/61\/16\/6105","volume":"61","author":"G Valdes","year":"2016","unstructured":"Valdes G, Solberg TD, Heskel M, Ungar L, Simone CB 2. Using machine learning to predict radiation pneumonitis in patients with stage I non-small cell lung cancer treated with stereotactic body radiation therapy. Phys Med Biol. 2016;61(16):6105\u201320. nd. .","journal-title":"Phys Med Biol"},{"key":"2136_CR7","doi-asserted-by":"publisher","first-page":"153303382110163","DOI":"10.1177\/15330338211016373","volume":"20","author":"M Yakar","year":"2021","unstructured":"Yakar M, Etiz D, Metintas M, Ak G, Celik O. Prediction of Radiation Pneumonitis With Machine Learning in Stage III Lung Cancer: A Pilot Study. Technol Cancer Res Treat. 2021;20:15330338211016373.","journal-title":"Technol Cancer Res Treat"},{"key":"2136_CR8","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.radonc.2020.10.040","volume":"155","author":"V Bourbonne","year":"2021","unstructured":"Bourbonne V, Da-Ano R, Jaouen V, Lucia F, Dissaux G, Bert J, et al. Radiomics analysis of 3D dose distributions to predict toxicity of radiotherapy for lung cancer. Radiother Oncol. 2021;155:144\u201350.","journal-title":"Radiother Oncol"},{"key":"2136_CR9","doi-asserted-by":"publisher","first-page":"768152","DOI":"10.3389\/fonc.2022.768152","volume":"12","author":"C Puttanawarut","year":"2022","unstructured":"Puttanawarut C, Sirirutbunkajorn N, Tawong N, Jiarpinitnun C, Khachonkham S, Pattaranutaporn P, et al. Radiomic and Dosiomic Features for the Prediction of Radiation Pneumonitis Across Esophageal Cancer and Lung Cancer. Front Oncol. 2022;12:768152.","journal-title":"Front Oncol"},{"key":"2136_CR10","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.ejrad.2016.09.005","volume":"86","author":"G Lee","year":"2017","unstructured":"Lee G, Lee HY, Park H, Schiebler ML, van Beek EJR, Ohno Y, et al. Radiomics and its emerging role in lung cancer research, imaging biomarkers and clinical management: State of the art. Eur J Radiol. 2017;86:297\u2013307.","journal-title":"Eur J Radiol"},{"key":"2136_CR11","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.lungcan.2017.10.015","volume":"115","author":"R Thawani","year":"2018","unstructured":"Thawani R, McLane M, Beig N, Ghose S, Prasanna P, Velcheti V, et al. Radiomics and radiogenomics in lung cancer: A review for the clinician. Lung cancer (Amsterdam Netherlands). 2018;115:34\u201341.","journal-title":"Lung cancer (Amsterdam Netherlands)"},{"issue":"4","key":"2136_CR12","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.ijrobp.2014.07.020","volume":"90","author":"DV Fried","year":"2014","unstructured":"Fried DV, Tucker SL, Zhou S, Liao Z, Mawlawi O, Ibbott G, et al. Prognostic value and reproducibility of pretreatment CT texture features in stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2014;90(4):834\u201342.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"2136_CR13","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s13014-018-1140-9","volume":"13","author":"W Sun","year":"2018","unstructured":"Sun W, Jiang M, Dang J, Chang P, Yin FF. Effect of machine learning methods on predicting NSCLC overall survival time based on Radiomics analysis. Radiation Oncol (London England). 2018;13(1):197.","journal-title":"Radiation Oncol (London England)"},{"issue":"7","key":"2136_CR14","doi-asserted-by":"publisher","first-page":"e197416","DOI":"10.1001\/jamanetworkopen.2019.7416","volume":"2","author":"MT Lu","year":"2019","unstructured":"Lu MT, Ivanov A, Mayrhofer T, Hosny A, Aerts H, Hoffmann U. Deep Learning to Assess Long-term Mortality From Chest Radiographs. JAMA Netw open. 2019;2(7):e197416.","journal-title":"JAMA Netw open"},{"issue":"7","key":"2136_CR15","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1080\/0284186X.2020.1750693","volume":"59","author":"M Duijm","year":"2020","unstructured":"Duijm M, van der Voort van Zyp NC, Granton PV, van de Vaart P, Mast ME, Oomen-de Hoop E, et al. Prognostic factors of local control and disease free survival in centrally located non-small cell lung cancer treated with stereotactic body radiation therapy. Acta Oncol. 2020;59(7):809\u201317.","journal-title":"Acta Oncol"},{"issue":"1","key":"2136_CR16","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ijrobp.2019.09.037","volume":"106","author":"J Kang","year":"2020","unstructured":"Kang J, Ning MS, Feng H, Li H, Bahig H, Brooks ED, et al. Predicting 5-Year Progression and Survival Outcomes for Early Stage Non-small Cell Lung Cancer Treated with Stereotactic Ablative Radiation Therapy: Development and Validation of Robust Prognostic Nomograms. Int J Radiat Oncol Biol Phys. 2020;106(1):90\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"2136_CR17","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.prro.2021.06.004","volume":"11","author":"B Qiu","year":"2021","unstructured":"Qiu B, Xiong M, Luo Y, Li Q, Chen N, Chen L, et al. Hypofractionated Intensity Modulated Radiation Therapy With Concurrent Chemotherapy in Locally Advanced Non-Small Cell Lung Cancer: A Phase II Prospective Clinical Trial (GASTO1011). Pract Radiat Oncol. 2021;11(5):374\u201383.","journal-title":"Pract Radiat Oncol"},{"issue":"5","key":"2136_CR18","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1016\/j.ijrobp.2010.07.1977","volume":"81","author":"FM Kong","year":"2011","unstructured":"Kong FM, Ritter T, Quint DJ, Senan S, Gaspar LE, Komaki RU, et al. Consideration of dose limits for organs at risk of thoracic radiotherapy: atlas for lung, proximal bronchial tree, esophagus, spinal cord, ribs, and brachial plexus. Int J Radiat Oncol Biol Phys. 2011;81(5):1442\u201357.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"16","key":"2136_CR19","doi-asserted-by":"publisher","first-page":"4786","DOI":"10.1158\/0008-5472.CAN-18-0125","volume":"78","author":"C Nioche","year":"2018","unstructured":"Nioche C, Orlhac F, Boughdad S, Reuz\u00e9 S, Goya-Outi J, Robert C, et al. LIFEx: A Freeware for Radiomic Feature Calculation in Multimodality Imaging to Accelerate Advances in the Characterization of Tumor Heterogeneity. Cancer Res. 2018;78(16):4786\u20139.","journal-title":"Cancer Res"},{"issue":"3","key":"2136_CR20","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1023\/B:STCO.0000035301.49549.88","volume":"14","author":"AJ Smola","year":"2004","unstructured":"Smola AJ, Scholkopf B. A tutorial on support vector regression. Stat Comput. 2004;14(3):199\u2013222.","journal-title":"Stat Comput"},{"issue":"1","key":"2136_CR21","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1148\/radiology.191.1.8134584","volume":"191","author":"MT Wu","year":"1994","unstructured":"Wu MT, Chang JM, Chiang AA, Lu JY, Hsu HK, Hsu WH, et al. Use of quantitative CT to predict postoperative lung function in patients with lung cancer. Radiology. 1994;191(1):257\u201362.","journal-title":"Radiology"},{"issue":"1","key":"2136_CR22","doi-asserted-by":"publisher","first-page":"11509","DOI":"10.1038\/s41598-019-48023-5","volume":"9","author":"KJ Lafata","year":"2019","unstructured":"Lafata KJ, Zhou Z, Liu JG, Hong J, Kelsey CR, Yin FF. An Exploratory Radiomics Approach to Quantifying Pulmonary Function in CT Images. Sci Rep. 2019;9(1):11509.","journal-title":"Sci Rep"},{"issue":"1","key":"2136_CR23","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s12931-019-1049-3","volume":"20","author":"M Occhipinti","year":"2019","unstructured":"Occhipinti M, Paoletti M, Bartholmai BJ, Rajagopalan S, Karwoski RA, Nardi C, et al. Spirometric assessment of emphysema presence and severity as measured by quantitative CT and CT-based radiomics in COPD. Respir Res. 2019;20(1):101.","journal-title":"Respir Res"},{"issue":"4","key":"2136_CR24","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1007\/s00330-011-2319-8","volume":"22","author":"B Ganeshan","year":"2012","unstructured":"Ganeshan B, Panayiotou E, Burnand K, Dizdarevic S, Miles K. Tumour heterogeneity in non-small cell lung carcinoma assessed by CT texture analysis: a potential marker of survival. Eur Radiol. 2012;22(4):796\u2013802.","journal-title":"Eur Radiol"},{"issue":"1","key":"2136_CR25","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S0360-3016(01)01772-2","volume":"52","author":"JD Bradley","year":"2002","unstructured":"Bradley JD, Ieumwananonthachai N, Purdy JA, Wasserman TH, Lockett MA, Graham MV, et al. Gross tumor volume, critical prognostic factor in patients treated with three-dimensional conformal radiation therapy for non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys. 2002;52(1):49\u201357.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"2136_CR26","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1016\/j.ijrobp.2011.10.065","volume":"83","author":"JL Lopez Guerra","year":"2012","unstructured":"Lopez Guerra JL, Gomez D, Zhuang Y, Levy LB, Eapen G, Liu H, et al. Change in diffusing capacity after radiation as an objective measure for grading radiation pneumonitis in patients treated for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2012;83(5):1573\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"2136_CR27","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3857\/roj.2013.31.1.34","volume":"31","author":"YH Park","year":"2013","unstructured":"Park YH, Kim JS. Predictors of radiation pneumonitis and pulmonary function changes after concurrent chemoradiotherapy of non-small cell lung cancer. Radiation Oncol J. 2013;31(1):34\u201340.","journal-title":"Radiation Oncol J"},{"issue":"1","key":"2136_CR28","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s12931-018-0775-2","volume":"19","author":"L Torre-Bouscoulet","year":"2018","unstructured":"Torre-Bouscoulet L, Mu\u00f1oz-Monta\u00f1o WR, Mart\u00ednez-Brise\u00f1o D, Lozano-Ruiz FJ, Fern\u00e1ndez-Plata R, Beck-Maga\u00f1a JA, et al. Abnormal pulmonary function tests predict the development of radiation-induced pneumonitis in advanced non-small cell lung Cancer. Respir Res. 2018;19(1):72.","journal-title":"Respir Res"},{"issue":"6","key":"2136_CR29","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s00066-019-01552-4","volume":"196","author":"Y Zhou","year":"2020","unstructured":"Zhou Y, Yan T, Zhou X, Cao P, Luo C, Zhou L, et al. Acute severe radiation pneumonitis among non-small cell lung cancer (NSCLC) patients with moderate pulmonary dysfunction receiving definitive concurrent chemoradiotherapy: Impact of pre-treatment pulmonary function parameters. Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft [et al]. 2020;196(6):505\u201314.","journal-title":"Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft [et al]"},{"key":"2136_CR30","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.semcancer.2019.12.021","volume":"65","author":"LC Dieterich","year":"2020","unstructured":"Dieterich LC, Bikfalvi A. The tumor organismal environment: Role in tumor development and cancer immunotherapy. Sem Cancer Biol. 2020;65:197\u2013206.","journal-title":"Sem Cancer Biol"},{"issue":"1","key":"2136_CR31","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1158\/2326-6066.CIR-19-0476","volume":"8","author":"M Khorrami","year":"2020","unstructured":"Khorrami M, Prasanna P, Gupta A, Patil P, Velu PD, Thawani R, et al. Changes in CT Radiomic Features Associated with Lymphocyte Distribution Predict Overall Survival and Response to Immunotherapy in Non-Small Cell Lung Cancer. Cancer Immunol Res. 2020;8(1):108\u201319.","journal-title":"Cancer Immunol Res"},{"issue":"2","key":"2136_CR32","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.ijrobp.2008.08.052","volume":"74","author":"C Dehing-Oberije","year":"2009","unstructured":"Dehing-Oberije C, Yu S, De Ruysscher D, Meersschout S, Van Beek K, Lievens Y, et al. Development and external validation of prognostic model for 2-year survival of non-small-cell lung cancer patients treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2009;74(2):355\u201362.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"20","key":"2136_CR33","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017;377(20):1919\u201329.","journal-title":"N Engl J Med"},{"issue":"24","key":"2136_CR34","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","volume":"379","author":"SJ Antonia","year":"2018","unstructured":"Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med. 2018;379(24):2342\u201350.","journal-title":"N Engl J Med"},{"issue":"Suppl 13","key":"2136_CR35","first-page":"1482-s93","volume":"10","author":"L Peng","year":"2018","unstructured":"Peng L, Wu YL. Immunotherapy in the Asiatic population: any differences from Caucasian population? J Thorac disease. 2018;10(Suppl 13):1482-s93.","journal-title":"J Thorac disease"},{"issue":"1","key":"2136_CR36","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1593\/tlo.13865","volume":"7","author":"B Zhao","year":"2014","unstructured":"Zhao B, Tan Y, Tsai WY, Schwartz LH, Lu L. Exploring Variability in CT Characterization of Tumors: A Preliminary Phantom Study. Translational Oncol. 2014;7(1):88\u201393.","journal-title":"Translational Oncol"},{"issue":"9","key":"2136_CR37","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/j.acra.2018.10.013","volume":"26","author":"EL Lu","year":"2019","unstructured":"Lu EL, Li L, Yang L, Schwartz H, Zhao LH. B. Radiomics for Classification of Lung Cancer Histological Subtypes Based on Nonenhanced Computed Tomography. Acad Radiol. 2019;26(9):1245\u201352.","journal-title":"Acad Radiol"},{"issue":"1","key":"2136_CR38","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2967\/jnumed.112.107375","volume":"54","author":"GJ Cook","year":"2013","unstructured":"Cook GJ, Yip C, Siddique M, Goh V, Chicklore S, Roy A, et al. Are pretreatment 18F-FDG PET tumor textural features in non-small cell lung cancer associated with response and survival after chemoradiotherapy? Journal of nuclear medicine: official publication. Soc Nuclear Med. 2013;54(1):19\u201326.","journal-title":"Soc Nuclear Med"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-022-02136-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-022-02136-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-022-02136-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T12:07:34Z","timestamp":1668600454000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-022-02136-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,16]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2136"],"URL":"https:\/\/doi.org\/10.1186\/s13014-022-02136-w","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,16]]},"assertion":[{"value":"7 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted based on the ethical standards of the Declaration of Helsinki. It was reviewed and approved by the review board of Sun Yat-sen University Cancer Center. Since it was an anonymous retrospective study, we required and were granted a waiver of written informed-consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"184"}}